Kornimate/medical-research-clean huggingface dataset:
brazilian diabetes study: a type 2 diabetes prospective cohort

Conditions: Cardiovascular Diseases; Diabete Mellitus; Coronary Artery Disease

Summary: ongoing prospective cohort of type 2 diabetes individuals.

the study population included individuals with type 2 diabetes aged between 40 and 70 years old, living in the metropolitan area of campinas, brazil. the volunteers were recruited between 2016 and 2020 through radio, newspaper, television and social media advertisements. a total of 1046 participants were enrolled into the study so far. all participants were firstly invited to an interview with the physician-researcher for medical story register and physical examination. afterwards, all participants were submitted to the following procedures: blood and urine samples collection, dual-energy x-ray absorptiometry, 6 minutes walk test, hand strength test, bone densitometry test, diabetic polyneuropathy evaluation, advanced glycation end-product measurement, electrocardiogram, echocardiogram, carotid doppler ultrasound, flow-mediated dilation, diabetic retinopathy assessment, ambulatory blood pressure monitoring and cardiac computed tomography for calcium scoring. after full examination, patients were contacted every year for 5 years for endpoints registration. the primary endpoint was a composite of all-cause mortality, myocardial infarction, stroke and myocardial revascularization. secondary endpoints were end-stage kidney disease requiring dialysis and limb amputation. study data were collected and managed using redcap electronic data capture tools.

Eligibility criteria:
inclusion criteria: * diagnosed type 2 diabetes * age between 40 and 70 years old exclusion criteria: * unconfirmed diagnosis of diabetes * intellectual disability

Keywords: diabetes cardiovascular disease
genetic polymorphisms & the risk for sepsis after trauma

Conditions: Trauma

Summary: the specific aim of this is to establish a cohort of severely injured patients admitted to our trauma center. investigators will collect dna, utilizing discarded blood samples, from 3000 injury victims in an effort to identify perhaps 50 - 100 single-nucleotide polymorphisms (snp) (out of 1000s) that can be used, when taken together, to identify patients at highest risk for developing complicated sepsis and death.

the specific aim of this is to establish a cohort of severely injured patients admitted to our trauma center. investigators will collect dna, utilizing discarded blood samples, from 3000 injury victims in an effort to identify perhaps 50 - 100 single-nucleotide polymorphisms (snp) (out of 1000s) that can be used, when taken together, to identify patients at highest risk for developing complicated sepsis and death

Eligibility criteria:
inclusion criteria: admitted to the intensive care unit (icu) at harborview medical center after suffering a traumatic injury * ability to obtain a 5 ml blood sample * expected to be in the icu for more than 24 hours exclusion criteria: * we will exclude subjects with chronic medical conditions for the reasons stated above as well as vulnerable populations (children, pregnant females, and prisoners)

Keywords: trauma sepsis
efficacy of pegintron and rebetol in previously untreated patients with chronic hepatitis c infected with hcv genotype 1/4/5/6 (study p04243)

Conditions: Hepatitis C, Chronic

Summary: the objective of the study is to evaluate the effectiveness of pegintron plus rebetol combination in treating patients with chronic hepatitis c in a primary care setting. patients received no antiviral therapy prior to the current study. only patients infected with hepatitis c virus (hcv) genotype 1, 4, 5, or 6 will be enrolled in the study. the study will also explore the influence of liver fibrosis stage on the chances of achieving a sustained virologic response.


Eligibility criteria:
inclusion criteria: * previously untreated ('treatment naïve') adults (18 year or more) for whom the treating physician has decided to start treatment with pegintron and rebetol * detectable hepatitis c virus - ribonucleic acid (hcv-rna) in serum by polymerase chain reaction (pcr) * repeated (with at least a 1 month interval) serum transaminase (alanine aminotransferase \[alt\]) levels above the upper normal limit for gender * documented chronic hepatitis c (chc) of genotype 1/4/5/6 * a representative liver biopsy within 1 year prior to inclusion, allowing fibrosis grading into metavir score f0, f1, f2, f3 or f4 exclusion criteria: * known hypersensitivity for any active ingredient or constituent * pregnancy or lactation * medically documented history of severe psychiatric disturbance, including severe depression, suicidal ideation or suicide attempt * medically documented history of severe heart disease, including unstable or uncontrolled cardiac disease, within the last 6 months * severely weakening medical condition, including chronic renal insufficiency or creatinine clearance \<50 ml/minute * hepatitis of immunologic origin or medically documented history of auto-immune disease * severe hepatic disorder or decompensated cirrhosis * pre-existing thyroid disorder, except if under control with classical treatment * epilepsy or central nervous system disorder * hemoglobin pathology, eg, thalassaemia, sickle cell anemia

Keywords: hepatitis c
profiling implantable cardiac device diagnostics trends during clinical events .

Conditions: Cardiovascular Diseases

Summary: the study looks to evaluate the device diagnostic data obtained from (all the cardiac rhythm and heart failure (crhf) devices of medtronic having the cardiac compass® and optivol® diagnostic feature) these devices to identify trends during clinical events that will help early detection and prevention of cardiovascular and other comorbid conditions. (i.e. heart failure(hf), atrial fibrilation,copd, renal dysfunction (rd), diabetes etc.)

this is a multi-center, non-randomized, non-interventional, data collection study with no subject follow-up visits required. subjects will be enrolled and exited from the study during the same study visit. the final analysis on the study will occur when 50 clinical events are reported on the study.all medtronic implantable cardiac rhythm and heart failure devices with the cardiac compass® and optivol® feature which are commercially available at the start of the registry or become commercially available during the course of the registry and used within its intended use, may be included in the study. after obtaining the informed consent patients will be interviewed to complete the "patient interview questionnaire". the study team will review medical records and complete the "medical record review" form as completely as possible. the device will then be interrogated to download the cardiac compass® report in a "save-to-disk" file and print the cardiac compass® report for the pi or the designated clinician from the study team for review. the "device interrogation questionnaire" will then be discussed with the patient for specific events identified on the cardiac compass® report in order to determine possible explanations and fill out the questionnaire as completely as possible. after collection of all the study related data the patient will be exited on the same visit, so a followup visit is not required in the study.

Eligibility criteria:
inclusion criteria: 1. subject must be greater than 18 years of age. 2. subject must have an implanted medtronic crhf device (with the optivol® and cardiac compass® diagnostics) for at least 1 year. 3. subjects between 18 years and 62 years of age must have at least 1 clinical event ,such as any major medication change, iv drug therapy, hospitalization, outside home-treatment or any similar event in the past 1 year from the date of enrollment which required a pharmacologic intervention, associated with any of the following comorbid conditions : * heart failure * chronic obstructive pulmonary disease (copd) * renal deficiency * atrial fibrillation * diabetes 4. subjects who are currently hospitalized with an index clinical event can also be enrolled. 5. if the subject is over 62 years of age then subject can be enrolled in the study without any pre-condition of a clinical event associated with a comorbid condition. exclusion criteria: * subject is unwilling or unable to give informed consent
perioperative pain and delirium in geriatric patients with hip fracture

Conditions: Delirium; Delirium in Old Age; Hip Fractures; Dementia; Pain; Analgesia; Mental Status Change

Summary: the objective of this trial will be to establish whether the ultrasound-guided suprainguinal fascia iliaca compartment block is capable of protecting geriatric patients with hip fracture from delirium as compared to placebo

geriatric patients suffer from hip fractures very often. delirium is a perioperative neuropsychiatric complication that is characterized by sudden change of mental status, inattention, disorientation and memory impairment with fluctuations of symptoms during the day. delirium causes increased morbidity and mortality, decreased postoperative functional activity and may predispose to dementia. perioperative pain may be an important predisposing factor to delirium. intravenous opioids have been widely used to relieve patients with hip fracture from pain, but they have a lot of complications and have been correlated with delirium as well. fascia iliaca compartment block is a peripheral compartment nerve block that is used in hip surgeries. use of this compartment nerve block to protect geriatric patients from delirium has not been studied. the objective of this trial will be to establish whether the ultrasound-guided suprainguinal fascia iliaca compartment block is capable of protecting geriatric patients with hip fracture from delirium as compared to placebo

Eligibility criteria:
inclusion criteria: * geriatric patients * american society of anesthesiologists (asa) i-iii * hip fracture patients exclusion criteria: * dementia * communication or language barriers * patients with nutritional problems * bedridden patients
description of bullous emphysema using lung ultrasound and comparison to the characteristics of pneumothorax

Conditions: Pulmonary Emphysema

Summary: chronic obstructive pulmonary disease (copd) is a frequent disease affecting a growing number of adults in the world which is responsible for a large public health burden through heavy morbidity and mortality. emphysema is one of a wide spectrum of pulmonary complications linked to copd, defined as the abnormal permanent enlargement of the airspaces distal to the terminal bronchioles accompanied by destruction of the alveolar wall. disease progression is correlated to worsening and enlargement of emphysema lesions, sometimes conflating in sizeable bullae, deleterious to normal mechanical pulmonary function. bullous emphysema (be) is sometimes eligible to invasive curative treatment through surgery or interventional bronchoscopy. diagnosis of be relies on computerized tomodensitometry (ct), the gold-standard for evaluating pulmonary parenchyma. however, ct is not always available, and bullous emphysema can present as pneumothorax on chest radiography. the practice of lung ultrasound is currently growing in respiratory medicine and emergency departments owing to an increasing amount of evidence showcasing its reliability as a diagnostic tool, most notably for pneumothorax and other pleural diseases. despite be having been reported to present similarly to pneumothorax in ultrasound, its characteristics have not yet been precisely described. the primary aim of this study is to describe be using lung ultrasound. participants with known be on ct will undergo a simple ultrasound examination. the secondary aim is to compare the characteristics of be to those of pneumothorax using lung ultrasound. to achieve this, a second group of participants with currently treated pneumothorax will also undergo lung ultrasound.


Eligibility criteria:
inclusion criteria: * bullous emphysema group * consultation or scheduled hospitalization in a pulmonary medicine department * past medical history of emphysema on computerized tomodensitometry dating less than two years * bullous emphysema with subpleural contact of two or more intercostal spaces on tomodensitometry * pneumothorax group * hospitalized in a pulmonary medicine department for the treatment of a pneumothorax * patent pneumothorax visible on chest x-ray dating less than 24 hours exclusion criteria: * bullous emphysema group * current pneumothorax * past medical history of pleurodesis or pleural thickening homolateral to the bullous emphysema * all patients * organ failure (hemodynamic, neurological, respiratory) * recent thoracic surgery dating less than 7 days with subcutaneous emphysema * minor participant or otherwise deprived of their freedom or their ability to consent freely * no affiliation to social security

Keywords: lung ultrasound
olanzapine versus lithium in the treatment of acute depression in patients with bipolar ii or bipolar not otherwise specified(ol study)

Conditions: Bipolar Disorder

Summary: determine the efficacy and tolerability of olanzapine for treatment of acute depression in patients with bipolar ii or bipolar disorder nos compared with lithium.


Eligibility criteria:
inclusion criteria: * major depressive episode in type2 bipolar disorder or bipolar disorder nos.(madrs more than 20 point) * 18years to 65years * subjects who sign the informed consent document exclusion criteria: * don't have diabetes and abnormal metabolism of sugar * not noticed as bipolar disorder * have an organic brain disease * pregnant or breastfeeding women * don't have heart disease * have actively suicidal thought(suicidal ideation score of madrs is 6) * who are judged by the investigator to should be excluded from the study
effects of neural mobilization and stretching in piriformis syndrome

Conditions: Piriformis Syndrome

Summary: this study compares the effects of piriformis stretching and neural mobilization of the sciatic nerve in individuals with piriformis syndrome, a condition that is frequently characterized by hip and buttock pain and discomfort brought on by the piriformis muscle compressing the sciatic nerve.

in a study involving 40 patients diagnosed with sciatica, researchers aimed to investigate whether neural mobilization of the sciatic nerve or stretching of the piriformis muscle was more effective in treating piriformis syndrome. the patients were divided into two groups, each containing 20 individuals. group a underwent neural mobilization therapy, while group b performed piriformis muscle stretches, with both groups receiving treatment three times a week for two weeks. assessments, including visual analog scale (vas) for pain, hip range of motion (rom) in flexion, abduction, and external rotation, as well as the fair test, were conducted before and after the interventions.

Eligibility criteria:
inclusion criteria: * positive lasegue sign * positive piriformis sign * tenderness at sciatic notch (over piriformis muscle). exclusion criteria: * • prior surgery of lumbar spine (laminectomy) * unrecognized pelvic fracture * known case of renal stones * disc herniation in lumbar spine * myositis ossificans of piriformis muscle.

Keywords: physiotherapy piriformis stretching visual analog scale (vas) pain management fair test range of motion
efficacy study of chemotherapy to treat advanced or recurrent endometrial cancer

Conditions: Advanced or Recurrent Endometrial Cancer

Summary: the purpose of this study is to treat advanced or recurrent endometrial cancer, paclitaxel-containing regimen is the preferred chemotherapeutic regimen which is selected by most physicians. docetaxel may have similar efficacy and more favorable treatment related toxicity profile as tested in epithelial ovarian cancer trials. therefore, the investigators aimed to evaluate the efficacy and safety of docetaxel plus cisplatin in patients with advanced or recurrent endometrial cancer.


Eligibility criteria:
inclusion criteria: * histologically confirmed chemotherapy naïve endometrial cancer * one of following histology endometrioid, upsc, ccca, squamous, adenosquamous, mixed * figo stage ivb or recurrent endometrial cancer (incurable by surgery and/or rt) * at least one measurable lesion by recist on ct * ecog ps: 0-2 * age: 20-75 * adequate organ function bm: anc≥1,000/mm3, plt≥100x103/mm3 kidney: creatinine\<1.25 × unl이고, gfr ≥ 60 liver: ast, alt\< 3×unl, t- bil\<1.5 mg/ mm3 * informed consent * contraception during study period exclusion criteria: * previous chemotherapy * rt, hormone therapy, or immunotherapy within 1 month * other malignant disease * uncontrolled medical disease * infection requiring antibiotics * symptomatic chf, rf, angina, arrhythmia, etc. * neurosis or psychosis * pregnancy, breast-feeding * etc.
genetic and histopathologic characteristics of interstitial cystitis

Conditions: Interstitial Cystitis

Summary: genetic and histopathologic characteristics of interstitial cystitis


Eligibility criteria:
inclusion criteria: * male and female aged 19 yrs or greater * patients diagnosed with hunner lesion in interstitial cystitis and who is scheduled to undergo transurethral resection * patients diagnosed with bladder cancer and who is scheduled to undergo cystectomy exclusion criteria: * male and female under aged 20 yrs * a person whose area of bladder cancer is larger than that of the normal area * a person who is going to have a cystectomy after chemotherapy on bladder cancer
correlating microrna changes with sepsis outcomes

Conditions: Septicemia

Summary: this trial studies how changes in micrornas may correlate with sepsis outcomes. sepsis is a type of severe infection of the blood stream, and its diagnosis may be obscured by many other conditions such as surgery, trauma, and cancer. micrornas are biomarkers found in the blood and tissue. blood samples may help correlate changes in microrna expression to patient reactions to a sepsis infection.

primary objectives: i. to examine whether the cellular and viral micro ribonucleic acid (mirna) changes in plasma and peripheral mononuclear blood cells (pmncs) correlate with the diagnosis and outcome of sepsis. secondary objectives: i. to distinguish systemic inflammatory response syndrome (sirs) without infection from sepsis and septic shock. outline: patients are assigned to 1 of 2 groups. group a: patients undergo blood specimen collection at baseline (before surgery), the day after surgery, either the day of hospital discharge or the day of sepsis diagnosis, and 6 days after the baseline blood draw if still hospitalized. group b: patients undergo blood specimen collection at baseline (day of sepsis diagnosis), the day after baseline, and on day 7 from baseline if still hospitalized.

Eligibility criteria:
inclusion criteria: * electively scheduled for surgical operation that require general anesthesia and expected duration of hospitalization of longer than one day (for patients in perioperative evaluation \& management \[poem\]) or high clinical suspicion of sepsis by the emergency physician (for patients in emergency center) * ability to give informed consent. if the patient is incapacitated and unable to give informed consent, the next-of-kin or a person who has the power of attorney must be present for informed consent. * for patients in the emergency center only, two or more of the following sirs criteria: * leukocytes \> 12,000/mm\^3 or \ 10% immature (band) forms, provided that no filgrastim or pegfilgrastim was administered within 30 days and no leukemia * heart rate \> 90 beats/minute (min) * respiratory rate \> 20 breaths/min or partial pressure of carbon dioxide (co2) \< 32 mmhg * oral temperature \> 38 degrees celsius (c) or \ 37 degrees c or \< 35 degrees c exclusion criteria: * inability to give informed consent or a person who has power of attorney for medical decision is not available * being moribund (for patients in emergency center) or cancellation of surgery (for patients in poem) * active "do not resuscitate" or "do not intubate" order
atomoxetine hydrochloride versus placebo in taiwanese children and adolescents with adhd

Conditions: Attention Deficit Hyperactivity Disorder

Summary: the purpose of this protocol is to investigate the acute treatment efficacy, safety, and tolerability of atomoxetine on a once-daily dosing strategy in taiwanese children and adolescents with adhd.


Eligibility criteria:
inclusion criteria: * subject must have adhd that meet dsm-iv disease diagnostic criteria as well as severity criteria * subjects must be aged 6 to 16 years * subjects must not have taken any medication used to treat adhd or they must have completed the washout procedures * subjects must be able to swallow capsules * subjects must be of normal intelligence in the judgment of the investigator. normal intelligence is defined as being without evidence of significant general intellectual deficit and expected to achieve a score of 80 or more if formal iq testing were administered. exclusion criteria: * weigh less than 20 kg or more than 60 kg at study entry * have a history of bipolar i or ii disorder, psychosis, or pervasive developmental disorder * meet dsm-iv criteria for an anxiety disorder as assessed by the investigator * have a history of any seizure disorder (other than febrile seizures) or prior ecg abnormalities related to epilepsy, or subjects who have taken (or are currently taking) anticonvulsants for seizure control * subjects who have a history of severe allergies to more than 1 class of medications or multiple adverse drug reactions.
the efficacy of oral everolimus in patients with neovascular age-related macular degeneration

Conditions: Choroidal Neo-Vascular Age-onset Macular Degeneration; Age-related Macular Degeneration

Summary: the study will assess the safety and efficacy of everolimus (rad001) alone or in combination with lucentis in patients with neo-vascular age related macular degeneration (amd)


Eligibility criteria:
inclusion criteria: * patients with neovascular age-related macular degeneration (amd) * best corrected visual acuity ( bcva) of 20/40 or worse in study eye * patients with predominantly classic, minimally classic, or occult choroidal neovascularization in the macula of one eye (the study eye) who have had an inadequate response to vegf inhibitors in the study eye. inadequate response is defined as a gain of less than one line of visual acuity and persistent macular edema (central sub-fiel thickness ≥ 300 μm as measured by optical coherence tomography (oct) despite a minimum of 3 treatments with lucentis or avastin exclusion criteria: * any concurrent ocular condition in the study eye that may result in substantial change in vision during the study * uncontrolled medical conditions such as cancer, angina, diabetes, viral or fungal infections, impaired lung function, history of stroke * patients who have macular edema in the study eye that, in the judgment of the investigator, is unlikely to respond to treatment. examples of features that may guide the investigator's judgment about unresponsiveness are large regions of geographic atrophy, retinal angiomatous proliferation, or large regions of sub-retinal fibrosis. the presence of one of these features excludes a patient only if the investigator judges the study eye to have irreversible macular edema. * active bacterial, fungal or viral infections at the time of enrollment, e.g. hepatitis b or c infection. patients with risk factors for hepatitis b should be tested for hepatitis b viral load and serological markers at screening (a positive hbv-dna, hbsag). patients with risk factors for hepatitis c should be tested using hcvrna-pcr at screening. a clinical history of hepatitis b or hepatitis c will exclude the patient from the study. other protocol-defined inclusion/exclusion criteria may apply

Keywords: amd macular degeneration everolimus lucentis ranibizumab choroidal neo-vascular (cnv) age-onset macular degeneration age-related macular degeneration (amd)